secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001213900-24-075736
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali SPAC enters $2.5B stock merger with Semnur Pharmaceuticals
-----------------------------------------------------------------

- Equity value of $2.5B; consideration payable in Denali (New Semnur) common shares.
- Scilex (Semnur parent) buys 500k Denali Class B shares for $2M cash and 300k Scilex shares.
- Closing targeted for Q1 2025; subject to shareholder vote, HSR clearance, Nasdaq listing.
- Sponsor and directors commit to vote for deal; Scilex signs stockholder support agreement.
- Post-closing, Denali renamed Semnur Pharma; Scilex gets board designation rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024075736/0001213900-24-075736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024075736/ea0213186-8k425_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-075736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer